Merck: FDA Accepts For Priority Review BLA For Adult Invasive Pneumococcal Vaccine
KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) said Tuesday that the U.S. Food and Drug Administration accepted for priority review a Biologics License Application or BLA for V114 for the
Source: finanznachrichten.de